NasdaqGM:NRIXBiotechs
Why Nurix Therapeutics (NRIX) Is Back In The Spotlight
Nurix Therapeutics (NRIX) is in focus after enrolling the first patient in its global Phase 3 DAYBreak CLL-306 trial of BTK degrader bexobrutideg with Roche, alongside a separate $10 million milestone payment from Sanofi.
See our latest analysis for Nurix Therapeutics.
The latest clinical and partnership milestones appear to be feeding into building momentum in Nurix Therapeutics' stock, with a 90 day share price return of 56.82% and a 1 year total shareholder return of 159.45%. This...